Resolution Chemicals Limited

Parveen Bhatarah

Alan Kenneth Greenwood

Derek McHattie

Gary Hembra

Mark Philip Gamble

Jerome Thomas Garfield Carr-Brion

Mahmoud Aloui

Kenneth Alan Greenwood

A sterilizable particle-size reduction apparatus, component parts thereof and a method of sterilizing and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Particle size reduction apparatus, and use thereof

A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier.

Solvent-based sterilisation of pharmaceuticals

The present invention provides a process for handling &#x394;9-THC, which comprises preparing a solution of &#x394;9-THC in a solvent which exists as a gas at room temperature and atmospheric pressure. The invention also provides solutions of &#x394;9-THC in the solvent and solid preparations of &#x394;9-THC.

Delta 9&#x2014;tetrahydrocannabinol processing

Particle-size reduction apparatus, and use thereof

A process for the syntheses of 17&#x3b2;-hydroxy-7&#x3b1;-methyl-19-nor-17&#x3b1;-pregn-5(10)-ene-20-yne-3-one (tibolone, 11) and intermediates useful for the synthesis thereof. 

Process for the production of tibolone

A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilizing and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Particle-size reduction apparatus and use thereof

A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and a p-disubstituted benzene of formula (A) or 1,3,5-trimethylbenzene and obtaining cabergoline Form I from the solvate. Another aspect of the present invention provides a method for preparing cabergoline Form I comprising dissolving cabergoline in p-disubstituted benzene or 1,3,5-trimethylbenzene and recovering the cabergoline Form I polymorph, suitably by direct crystallization of Form I or by recovery of a solvate which can be converted to Form I. Another aspect of the present invention provides a novel cabergoline polymorph designated cabergoline Form Fand a method of preparing said polymorph by dissolving or forming a solvate of cabergoline in fluorobenzene and recovering cabergoline Form F.

Preparation of cabergoline

The present invention discloses a method for preparing cabergoline form I by combining cabergoline and a solvent comprising ethylbenzene to form a solvate and obtaining form I from the solvate. Also disclosed in a method for preparing cabergoline form I by combining cabergoline and a first solvent to form a solution and additionally including a second solvent to the solution, followed by crystallization to form cabergoline form I. Further disclosed is a solvate form of cabergoline comprising cabergoline and ethylbenzene and, optionally, n-heptane.

Growing community of inventors

Middlesex, United Kingdom

Parveen Bhatarah